<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01302067</url>
  </required_header>
  <id_info>
    <org_study_id>A0221095</org_study_id>
    <secondary_id>EIGHT</secondary_id>
    <nct_id>NCT01302067</nct_id>
  </id_info>
  <brief_title>A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine</brief_title>
  <official_title>A 12-Week, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Trial In Overactive Bladder Subjects To Confirm The Efficacy Of 8 Mg Fesoterodine Compared To 4 Mg Fesoterodine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to confirm if 8mg of fesoterodine is more effective in reducing
      overactive bladder symptoms than 4mg of fesoterodine. In addition the study is designed to
      assess if the higher dose reduces the overall effect of overactive bladder on the subject's
      daily life more than the lower dose. The study also assesses the side effects and safety of
      the two doses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>UUI episodes were defined as those with the Urinary Sensation Scale (USS) rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 4.</measure>
    <time_frame>Week 4</time_frame>
    <description>Micturitions include episodes of voluntary micturition and episodes of UUI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>Micturitions include episodes of voluntary micturition and episodes of UUI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Micturitions Per 24 Hours at Week 4.</measure>
    <time_frame>Week 4</time_frame>
    <description>Micturitions include episodes of voluntary micturition and episodes of UUI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Micturitions Per 24 Hours at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>Micturitions include episodes of voluntary micturition and episodes of UUI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of UUI Episodes Per 24 Hours at Week 4.</measure>
    <time_frame>Week 4</time_frame>
    <description>UUI episodes were defined as those with the USS rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of UUI Episodes Per 24 Hours at Week 4.</measure>
    <time_frame>Week 4</time_frame>
    <description>UUI episodes were defined as those with the USS rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of UUI Episodes Per 24 Hours at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>UUI episodes were defined as those with the USS rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Micturition-Related Urgency Episodes Per 24 Hours at Week 4.</measure>
    <time_frame>Week 4</time_frame>
    <description>The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to (&gt;=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Micturition-Related Urgency Episodes Per 24 Hours at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to (&gt;=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Micturition-Related Urgency Episodes Per 24 Hours at Week 4.</measure>
    <time_frame>Week 4</time_frame>
    <description>The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to (&gt;=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Micturition-Related Urgency Episodes Per 24 Hours at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to (&gt;=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in Patient Perception of Bladder Condition (PPBC) at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>PPBC: a self-administered, single-item, questionnaire that asks participants to describe their perception of their bladder-related problems. The PPBC assessment is rated on a 6-point scale: 1=no problems at all, 2=some very minor problems, 3=some minor problems, 4=moderate problems, 5=severe problems, 6=many severe problems. Improvement is defined as negative change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in Urgency Perception Scale (UPS) at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>UPS: single-item, self-administered validated questionnaire. Participant answered: &quot;Which of the following would typically describe your experience when you have a desire to urinate?&quot; on a 3-point scale, 1=usually not able to hold urine; 2=usually able to hold urine (without leaking) until I reach a toilet if I go to the toilet immediately; 3= usually able to finish what I am doing before going to the toilet (without leaking). Change = observation minus baseline. Results categorized as Deterioration (Negative change); no change (Score change=0); improvement (Positive change).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>OAB-q: a self-administered, 33-item, questionnaire that assesses how much the participant has been bothered by selected bladder symptoms. Each item rated by participant on Likert scale 1 (not at all) to 6 (a very great deal). Symptom bother score derived as sum of scores for questions 1-8; lowest possible raw score: 8; highest possible score: 48. Data analyzed based on transformation of the score to a 0 to 100 scale [(Actual total raw score - lowest possible value of raw score)/range]*100. Higher scores values indicative of greater symptom bother.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Related Quality of Life (HRQL)-Coping Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (not at all) to 6 (a very great deal). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Related Quality of Life (HRQL)-Concern Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (not at all) to 6 (a very great deal). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Related Quality of Life (HRQL)-Sleep Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (not at all) to 6 (a very great deal). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Related Quality of Life (HRQL)-Social Interaction Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (not at all) to 6 (a very great deal). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Related Quality of Life (HRQL)-Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (not at all) to 6 (a very great deal). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Became Dry at Week 4.</measure>
    <time_frame>Week 4</time_frame>
    <description>Percentage of participants with no UUI episode for the three day diary, the numerator being the number of participants with no UUI at a visit and the denominator the total number of participants with UUI&gt;0 at baseline. UUI episodes defined as those with USS rating of 5 (unable to hold; leak urine) in the diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Became Dry at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of participants with no UUI episode for the three day diary, the numerator being the number of participants with no UUI at a visit and the denominator the total number of participants with UUI &gt;0 at baseline. UUI episodes defined as those with USS rating of 5 (unable to hold; leak urine) in the diary.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2012</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Fesoterodine 8mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fesoterodine 4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fesoterodine 8mg</intervention_name>
    <description>Oral, 1 tablet per day, 12 weeks duration, 8mg/day</description>
    <arm_group_label>Fesoterodine 8mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fesoterodine 4mg</intervention_name>
    <description>Oral, 1 tablet per day, 12 weeks duration, 4mg/day</description>
    <arm_group_label>Fesoterodine 4mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral, 1 tablet per day, 12 weeks duration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6 months overactive bladder symptoms, minimum of 2 urgency urinary incontinence
             episodes per 24 hours and minimum of 8 micturitions per 24 hours.

        Exclusion Criteria:

          -  Other concurrent and concomitant medication or disease that could put the subjects at
             additional risk or interfere with the study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urology Centers of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Achieve Clinical Research, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Gordon McMurray, MD</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Affiliated Research Center, Inc.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mobile Ob-Gyn, P.C.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montgomery Women's Health Associates, P.C.</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scottsboro Quick Care Clinic</name>
      <address>
        <city>Scottsboro</city>
        <state>Alabama</state>
        <zip>35768</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dedicated Clinical Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genova Clinical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEA Baptist Women's Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A Clinic For Women</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Larry S. Watkins, MD</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of the Ozarks</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>May Women's Health Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Office of Dr. Simon Yassear, MD</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Citrus Valley Medical Research, Inc.</name>
      <address>
        <city>Glendora</city>
        <state>California</state>
        <zip>91741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grossmont Center for Clinical Research</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sockolov and Sockolov APC</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Clinical Trials</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Innovations, Inc.</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates, PC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genitourinary Surgical Consultants</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Women's Clinic of Northern Colorado</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80524</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Specialty Care</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uromedix</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Sleep Disorder Center of Brandon</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PAB Clinical Research</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates of Brandon</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research</name>
      <address>
        <city>Crystal River</city>
        <state>Florida</state>
        <zip>34429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Medical Center of Walton County</name>
      <address>
        <city>DeFuniak Springs</city>
        <state>Florida</state>
        <zip>32435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SJS Clinical Research, Inc.</name>
      <address>
        <city>Destin</city>
        <state>Florida</state>
        <zip>32541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fleming Island Center for Clinical Research</name>
      <address>
        <city>Fleming Island</city>
        <state>Florida</state>
        <zip>32003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M &amp; O Clinical Research, LLC</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Urology Physicians</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urological Research Network, LLC</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altus Research</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OB-GYN Associates of Mid-Florida, PA</name>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <zip>34748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Horizon Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Health Team, PLLC</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward Research Group</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Central Florida</name>
      <address>
        <city>Plant City</city>
        <state>Florida</state>
        <zip>33563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Research Group, Inc.</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced OBGYN Associates</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Central Florida</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Fulton Urology, PC</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Georgia Clinical Research</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Georgia Internal Medicine</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Healthcare Associates dba Rosemark WomenCare Specialists</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Practice</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <zip>61820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Women's Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical and Surgical Specialists</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Specialists, Inc.</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network of Indiana, LLC</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <zip>46123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Institute</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediSphere Medical Research Center, LLC</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network of Indiana, LLC</name>
      <address>
        <city>Greenfield</city>
        <state>Indiana</state>
        <zip>46140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Urology</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Clinic Gateway Health Center</name>
      <address>
        <city>Newburgh</city>
        <state>Indiana</state>
        <zip>47630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Healthcare</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Science Research Center</name>
      <address>
        <city>Pratt</city>
        <state>Kansas</state>
        <zip>67124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's and Family Care dba GTC Research</name>
      <address>
        <city>Shawnee</city>
        <state>Kansas</state>
        <zip>66218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Medical Research Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Commonwealth Biomedical Research</name>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates, Inc.</name>
      <address>
        <city>Mount Sterling</city>
        <state>Kentucky</state>
        <zip>40353</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sterling Clinic</name>
      <address>
        <city>Mount Sterling</city>
        <state>Kentucky</state>
        <zip>40353</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Office of Dr. Myron I. Murdock, MD, LLC</name>
      <address>
        <city>Greenbelt</city>
        <state>Maryland</state>
        <zip>20770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials, Inc.</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beacon Clinical Research, LLC</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Cape Cod, Inc.</name>
      <address>
        <city>Hyannis</city>
        <state>Massachusetts</state>
        <zip>02601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinity Medical Research</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Michigan, LLC</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRC of Jackson</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mississippi Urology Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Pharmaceutical Research</name>
      <address>
        <city>St. Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Health Care Center</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Clinic of Lincoln, P.C.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lincoln Internal Medicine Associates</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virtua Phoenix Ob-Gyn</name>
      <address>
        <city>Moorestown</city>
        <state>New Jersey</state>
        <zip>08057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Research, Inc.</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <zip>08611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Medical Associates</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooklyn Urology Research Group</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urological Surgeons of Long Island</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley</name>
      <address>
        <city>Kingston</city>
        <state>New York</state>
        <zip>12401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Hudson Medical Research, PLLC</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Research Associates</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kernodle Clinic, Inc.</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Clinical Trials</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urology Partners, PLLC</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Research Associates</name>
      <address>
        <city>Harrisburg</city>
        <state>North Carolina</state>
        <zip>28075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Associates</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Internal Medicine Consultants, Inc.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawthorne Medical Research, Inc. - Hawthorne OB/GYN Associates</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawthorne Medical Research, Inc.</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patient Priority Clinical Sites, LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Center for Women's Health Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Clinical Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hometown Urgent Care and Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HWC Women's Research Center</name>
      <address>
        <city>Englewood</city>
        <state>Ohio</state>
        <zip>45322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Clinical Research, LLC</name>
      <address>
        <city>Willoughby Hills</city>
        <state>Ohio</state>
        <zip>44094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Office of Johnny B. Roy, MD</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Clinical Research, LLC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Female Pelvic Medicine</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laurel Highlands OB/GYN</name>
      <address>
        <city>Hopwood</city>
        <state>Pennsylvania</state>
        <zip>15445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Trial Center, LLC</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richard Kastelic and Associates</name>
      <address>
        <city>Johnstown</city>
        <state>Pennsylvania</state>
        <zip>15405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research Services, LLC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triangle Urological Group</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Nittany Medical Center Health Services Inc. dba Mount Nittany Physician Group</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pish Medical Associates</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Concepts</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woman's Clinic Ltd.</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Medical</name>
      <address>
        <city>East Greenwich</city>
        <state>Rhode Island</state>
        <zip>02818</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Safe Harbor Clinical Research</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TLM Medical Services, LLC</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Urogynecology</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine and Pediatric Associates of Bristol, PC</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Bristol, LLC</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adams Patterson Gynocology and Obstetrics, PLLC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Medical PC</name>
      <address>
        <city>New Tazewell</city>
        <state>Tennessee</state>
        <zip>37825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Center for Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RJE Clinical Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Clinical Associates dba MCA Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACRC Trials (Administrative/Mailing Site)</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Texas Family Medicine</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Women's Health</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seven Oaks Women's Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78299</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Healthcare</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Healthcare</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research - Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independence Family Medicine</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Urology Research Center</name>
      <address>
        <city>Burien</city>
        <state>Washington</state>
        <zip>98166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAMC Clinical Trials Center</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAMC Physicians Group</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Internal Medicine, Inc.</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologic Surgical Center</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Specialists, Inc.</name>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <zip>53142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dean Oregon Clinic</name>
      <address>
        <city>Oregon</city>
        <state>Wisconsin</state>
        <zip>53575</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegiance Research Specialists</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Urologico Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1060AAA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Urologa (CDU)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1120AAS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Medico Especializado (IME)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1405BCH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Peter Pommerville</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V6T 5G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Can-Med Clinical Research</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Nazmuddin Merali</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Can-Med Clinical Research Incorporated</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 5G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharos Medical Research Ltd.</name>
      <address>
        <city>Grand Falls-Windsor</city>
        <state>Newfoundland and Labrador</state>
        <zip>A2A 2E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster Institute of Urology, St Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Bernard Goldfarb</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 7K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanley Flax Medical Professional Corporation</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M2J 1V1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urotec</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H 7K4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital, University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Urology Clinical Study Group</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6A 3B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology South Shore Research</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UroLaval</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7G 2E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ultra-Med Inc.</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Uromed</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <zip>7500787</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universidad de Chile</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <zip>8380456</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Centro de Investigacion Clinica CIC</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>0000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solano Y Terront Servicios Medicos Ltda / Unidad Integral de Endocrinologia Uniendo</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>0000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologicka ambulance</name>
      <address>
        <city>Benesov</city>
        <zip>25601</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN a LFUK Hradec Kralove/Urologicka klinika</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jablonec nad Nisou</name>
      <address>
        <city>Jablonec nad Nisou</city>
        <zip>466 60</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologicka klinika</name>
      <address>
        <city>Praha 1 - Nove Mesto</city>
        <zip>110 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole</name>
      <address>
        <city>Praha 5</city>
        <zip>15006</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Androgeos spol. s.r.o.</name>
      <address>
        <city>Praha 6 - Hradcany</city>
        <zip>160 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologicka ambulance</name>
      <address>
        <city>Znojmo</city>
        <zip>66902</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskilde sygehus, Gynaekologisk/obstetrisk afdeling</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Al-Azhar University hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kouvolan Lkriasema</name>
      <address>
        <city>Kouvola</city>
        <zip>45200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lkriasema Cantti Oy</name>
      <address>
        <city>Kuopio</city>
        <zip>70110</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hpital Edouard Herriot</name>
      <address>
        <city>Lyon Cedex 03</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Htel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hpital CAREMEAU - Service Urologie/Andrologie</name>
      <address>
        <city>Nimes Cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hpital Tenon - Service d'Urologie</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arztpraxis</name>
      <address>
        <city>Alzey</city>
        <zip>55232</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Berlin-Buch GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research GmbH</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Dresden GmbH</name>
      <address>
        <city>Dresden</city>
        <zip>01069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research GmbH</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research GmbH</name>
      <address>
        <city>Goerlitz</city>
        <zip>02826</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Hannover - Mitte GmbH</name>
      <address>
        <city>Hannover</city>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeinmedizin Praktische Aerzte</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arztpraxis</name>
      <address>
        <city>Lauenburg</city>
        <zip>21481</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMO MD GmbH</name>
      <address>
        <city>Magdeburg</city>
        <zip>39112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRS Clinical Research Service Moenchengladbach GmbH</name>
      <address>
        <city>Moenchengladbach</city>
        <zip>41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisklinik Urologie Rhein-Ruhr</name>
      <address>
        <city>Muelheim a.d. Ruhr</city>
        <zip>45468</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharzt fuer Urologie</name>
      <address>
        <city>Reutlingen</city>
        <zip>72764</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Schwerin GmbH</name>
      <address>
        <city>Schwerin</city>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Larisa/ Urology Department</name>
      <address>
        <city>Larisa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Papageorgiou</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Magyarorszag Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jahn Ferenc Del-pesti Korhaz, Urologiai Osztaly</name>
      <address>
        <city>Budapest</city>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Urologiai Klinika</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josa Andras Oktatokorhaz Egeszsegugyi Szolgaltato Nonprofit Kft., Urologiai osztaly</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit Magna Graecia di Catanzaro</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Urologica Centro Trapianti di rene</name>
      <address>
        <city>Foggia</city>
        <zip>71122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University College of Medicine, Department of Urology</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital, Department of Urology</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center, Department of Urology</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saules Seimos Medicinos Centras, JSC</name>
      <address>
        <city>Kaunas</city>
        <zip>49449</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mano Seimos Gydytojas, JSC</name>
      <address>
        <city>Klaipeda</city>
        <zip>94231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seimos Gydytojas, JSC</name>
      <address>
        <city>Vilnius</city>
        <zip>01118</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Lomas de San Luis Internacional</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78218</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medi 3 Elverum AS</name>
      <address>
        <city>Elverum</city>
        <zip>2408</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medi 3 Innlandet</name>
      <address>
        <city>Hamar</city>
        <zip>2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norsk Helseklinikk AS, c/o Heiaklinikken</name>
      <address>
        <city>Lierskogen</city>
        <zip>3420</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forusakutten AS, Avdeling for oppdragsforskning</name>
      <address>
        <city>Stavanger</city>
        <zip>4005</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perpetual Succour Hospital of Cebu Inc.</name>
      <address>
        <city>Cebu City</city>
        <state>Cebu</state>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Pablo O. Torre Memorial Hospital</name>
      <address>
        <city>Bacolod City</city>
        <zip>6100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Iloilo City</city>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Urologii Akademickie Centrum Kliniczne - Szpital Akademii Medycznej w Gdansku</name>
      <address>
        <city>Gdansk</city>
        <zip>80-402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Medyczne</name>
      <address>
        <city>Lodz</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Urologiczne Sp. z o. o.</name>
      <address>
        <city>Myslowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nzoz &quot;Nasz Lekarz&quot;</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-governmental Healthcare Institution Departmental Clinical Hospital at Barnaul station OAO RZD</name>
      <address>
        <city>Barnaul</city>
        <zip>656038</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov State Medical University, Chair of Urology</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Obstetrics and Gynaecology D.O. Otta of North-west Department of RAMS</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>199034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>URO CLINIC, s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>811 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruzinovska poliklinika, a.s.</name>
      <address>
        <city>Bratislava</city>
        <zip>820 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnica s Poliklinikou Svateho Lukasa Galanta</name>
      <address>
        <city>Galanta</city>
        <zip>924 22</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UROX s.r.o.</name>
      <address>
        <city>Piestany</city>
        <zip>921 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum urologie Povazska Bystrica, s.r.o. urologicka ambulancia</name>
      <address>
        <city>Povazska Bystrica</city>
        <zip>017 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica Trencin</name>
      <address>
        <city>Trencin</city>
        <zip>911 71</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UROGYN,s.r.o.</name>
      <address>
        <city>Zilina</city>
        <zip>010 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica s poliklinikou Zilina</name>
      <address>
        <city>Zilina</city>
        <zip>012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GYNPOR SK, s.r.o. Urogynekologicka ambulancia</name>
      <address>
        <city>Zvolen</city>
        <zip>960 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Unit</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinix Private Clinic</name>
      <address>
        <city>Vosloorus</city>
        <state>Gauteng</state>
        <zip>1475</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Centre</name>
      <address>
        <city>Roodepoort</city>
        <zip>1715</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carema Specialistvard Eslov</name>
      <address>
        <city>Eslov</city>
        <zip>241 23</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hagakliniken</name>
      <address>
        <city>Goteborg</city>
        <zip>413 28</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTC, Sahlgrenska sjukhuset/SU</name>
      <address>
        <city>Goteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Probare</name>
      <address>
        <city>Lund</city>
        <zip>222 22</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Lakemedelsstudier</name>
      <address>
        <city>Malmo</city>
        <zip>211 52</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ladulaas kliniska studier</name>
      <address>
        <city>Skene</city>
        <zip>511 62</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Verksamhet Urologi</name>
      <address>
        <city>Skovde</city>
        <zip>541 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kvinnokliniken Karolinska Universitetssjukhuset Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S3 Clinical Research Centers</name>
      <address>
        <city>Vallingby</city>
        <zip>162 68</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vasterviks sjukhus, Kvinnokliniken</name>
      <address>
        <city>Vastervik</city>
        <zip>593 81</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation. Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Department of Urology</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital/Division of Urology</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RMI &quot;Chernivtsi Regional Clinical Hosp.&quot;, Dep. of Urology, BSMU, Chair of Surgery and Urology</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #4 of Donetsk, Woman Consultative Department</name>
      <address>
        <city>Donetsk</city>
        <zip>83002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Urology of Donetsk National Medical University at Central City Clinical Hospital #1</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MTPI &quot;Central City Clinical Hospital #1&quot;/Donetsk National Medical University n.a. M. Gorkiy,</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzhorod City Outpatient Clinic, Prophylaxis Department</name>
      <address>
        <city>Uzhorod</city>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnitsa Regional Clinical Dispensary of Endocrinology</name>
      <address>
        <city>Vinnitsa</city>
        <zip>21010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Dept of Zaporizhzhia Medical Academy of Postgraduate Education</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fowey River Practice</name>
      <address>
        <city>Fowey</city>
        <state>Cornwall</state>
        <zip>PL23 1DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knowle House Surgery</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL5 3JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ormeau Health Centre</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT7 2EB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospital Trials NHS Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern General Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baillieston Health Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G69 7AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheepcot Medical Centre</name>
      <address>
        <city>Hertfordshire</city>
        <zip>WD2 6EB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Egypt</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0221095&amp;StudyName=A%2012%20week%20study%20to%20confirm%20the%20effectiveness%20of%208mg%20of%20fesoterodine%20compared%20to%204mg%20of%20fesoterodine</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2011</study_first_submitted>
  <study_first_submitted_qc>February 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <results_first_submitted>November 1, 2013</results_first_submitted>
  <results_first_submitted_qc>November 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 24, 2013</results_first_posted>
  <last_update_submitted>February 25, 2014</last_update_submitted>
  <last_update_submitted_qc>February 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fesoterodine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This report presents results of a 12-week study conducted at 241 centers across 27 countries.</recruitment_details>
      <pre_assignment_details>Participants 18 years of age with overactive bladder (OAB) symptoms for 6 months prior to screening were enrolled. After screening eligible participants were enrolled into the run-in period and received placebo for 2 weeks in a single-blind manner. Participants completed a 3-day bladder diary for 3 days in the week prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fesoterodine 4 Milligram (mg)</title>
          <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received one tablet of placebo per day for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Fesoterodine 8 mg</title>
          <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="790"/>
                <participants group_id="P2" count="386"/>
                <participants group_id="P3" count="779"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="712"/>
                <participants group_id="P2" count="352"/>
                <participants group_id="P3" count="681"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="98"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety analysis set included all participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Fesoterodine 4 Milligram (mg)</title>
          <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received one tablet of placebo per day for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Fesoterodine 8 mg</title>
          <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="790"/>
            <count group_id="B2" value="386"/>
            <count group_id="B3" value="779"/>
            <count group_id="B4" value="1955"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Years</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 to 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="380"/>
                    <measurement group_id="B2" value="193"/>
                    <measurement group_id="B3" value="377"/>
                    <measurement group_id="B4" value="950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="296"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="303"/>
                    <measurement group_id="B4" value="743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="647"/>
                    <measurement group_id="B2" value="316"/>
                    <measurement group_id="B3" value="627"/>
                    <measurement group_id="B4" value="1590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="152"/>
                    <measurement group_id="B4" value="365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12.</title>
        <description>UUI episodes were defined as those with the Urinary Sensation Scale (USS) rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
        <time_frame>Week 12</time_frame>
        <population>Full Analysis Set (FAS)included participants receiving 1 dose of assigned study drug and with 1 baseline (BL) or post-BL efficacy assessment. Last observation carried forward (LOCF) was used to impute missing data at Week 12. Participants with baseline UUI &gt;0 per 24 hours &amp; non-missing change from BL to Week 12 were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12.</title>
          <description>UUI episodes were defined as those with the Urinary Sensation Scale (USS) rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
          <population>Full Analysis Set (FAS)included participants receiving 1 dose of assigned study drug and with 1 baseline (BL) or post-BL efficacy assessment. Last observation carried forward (LOCF) was used to impute missing data at Week 12. Participants with baseline UUI &gt;0 per 24 hours &amp; non-missing change from BL to Week 12 were included.</population>
          <units>Episodes per 24 hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="733"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="718"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.85" spread="0.09"/>
                    <measurement group_id="O2" value="-2.22" spread="0.12"/>
                    <measurement group_id="O3" value="-3.12" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparisons were done with 2-sided test at 5% significance level. Null hypothesis: mean change from BL in the number of UUI episodes per 24 hours in the 8mg group was same as 4mg group at Week 12. ANCOVA was used to compare 8mg and 4mg arms for numeric change from BL - Week 12. This included terms for treatment, country, centered BL value and centered BL by treatment interaction, in which centered BL (BL  mean BL) was used to ensure that treatment effect was estimated at mean covariate value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Primary comparison was 8 mg VS. 4 mg (closed-testing method). Treatment effect of 8 mg VS. placebo was tested 1st. Treatment difference of 8 mg VS. 4 mg was tested if a statistically significant difference between 8 mg and placebo was shown.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Using a closed testing procedure, no adjustments of -level was needed at each stage of testing. Each was done at the 0.05 significance level.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.16</ci_lower_limit>
            <ci_upper_limit>-0.66</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons were performed with a two-sided test at the 5% significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0109</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>-0.06</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons were performed with a two-sided test at the 5% significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>-0.39</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 4.</title>
        <description>Micturitions include episodes of voluntary micturition and episodes of UUI.</description>
        <time_frame>Week 4</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with BL Micturition Frequency &gt;0 per 24 hours and non-missing change from BL to Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 4.</title>
          <description>Micturitions include episodes of voluntary micturition and episodes of UUI.</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with BL Micturition Frequency &gt;0 per 24 hours and non-missing change from BL to Week 4.</population>
          <units>Episodes per 24 hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="715"/>
                <count group_id="O2" value="364"/>
                <count group_id="O3" value="705"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.95" spread="0.13"/>
                    <measurement group_id="O2" value="-1.19" spread="0.16"/>
                    <measurement group_id="O3" value="-2.33" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, and centered baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-1.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.48</ci_lower_limit>
            <ci_upper_limit>-0.79</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, and centered baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0082</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.67</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, and centered baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.10</ci_lower_limit>
            <ci_upper_limit>-0.41</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12.</title>
        <description>Micturitions include episodes of voluntary micturition and episodes of UUI.</description>
        <time_frame>Week 12</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. LOCF was used to impute missing data at Week 12. The analysis included participants with BL Micturition Frequency &gt;0 per 24 hours and non-missing change from BL to Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12.</title>
          <description>Micturitions include episodes of voluntary micturition and episodes of UUI.</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. LOCF was used to impute missing data at Week 12. The analysis included participants with BL Micturition Frequency &gt;0 per 24 hours and non-missing change from BL to Week 12.</population>
          <units>Episodes per 24 hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="733"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="719"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.45" spread="0.13"/>
                    <measurement group_id="O2" value="-1.58" spread="0.17"/>
                    <measurement group_id="O3" value="-2.97" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, and centered baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-1.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.76</ci_lower_limit>
            <ci_upper_limit>-1.03</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, and centered baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, and centered baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.23</ci_lower_limit>
            <ci_upper_limit>-0.51</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Micturitions Per 24 Hours at Week 4.</title>
        <description>Micturitions include episodes of voluntary micturition and episodes of UUI.</description>
        <time_frame>Week 4</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with BL Micturition Frequency &gt;0 per 24 hours and non-missing change from BL to Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Micturitions Per 24 Hours at Week 4.</title>
          <description>Micturitions include episodes of voluntary micturition and episodes of UUI.</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with BL Micturition Frequency &gt;0 per 24 hours and non-missing change from BL to Week 4.</population>
          <units>Episodes per 24 hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="715"/>
                <count group_id="O2" value="364"/>
                <count group_id="O3" value="705"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.58" lower_limit="-65.71" upper_limit="96.30"/>
                    <measurement group_id="O2" value="-9.01" lower_limit="-60.94" upper_limit="95.00"/>
                    <measurement group_id="O3" value="-17.24" lower_limit="-70.91" upper_limit="117.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on a RANKED ANCOVA model with terms for treatment and pooled country with ranked baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Testing for percent change from baseline was only carried out for given endpoint if corresponding numeric change result was statistically significant.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on a RANKED ANCOVA model with terms for treatment and pooled country with ranked baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0040</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Testing for percent change from baseline was only carried out for given endpoint if corresponding numeric change result was statistically significant.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was based on a RANKED ANCOVA model with terms for treatment and pooled country with ranked baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Testing for percent change from baseline was only carried out for given endpoint if corresponding numeric change result was statistically significant.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Micturitions Per 24 Hours at Week 12.</title>
        <description>Micturitions include episodes of voluntary micturition and episodes of UUI.</description>
        <time_frame>Week 12</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. LOCF was used to impute missing data at Week 12. The analysis included participants with BL Micturition Frequency &gt;0 per 24 hours and non-missing change from BL to Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Micturitions Per 24 Hours at Week 12.</title>
          <description>Micturitions include episodes of voluntary micturition and episodes of UUI.</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. LOCF was used to impute missing data at Week 12. The analysis included participants with BL Micturition Frequency &gt;0 per 24 hours and non-missing change from BL to Week 12.</population>
          <units>Episodes per 24 hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="733"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="719"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.74" lower_limit="-64.58" upper_limit="92.59"/>
                    <measurement group_id="O2" value="-12.16" lower_limit="-64.04" upper_limit="95.00"/>
                    <measurement group_id="O3" value="-24.14" lower_limit="-76.74" upper_limit="78.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on a RANKED ANCOVA model with terms for treatment and pooled country with ranked baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Testing for percent change from baseline was only carried out for given endpoint if corresponding numeric change result was statistically significant.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on a RANKED ANCOVA model with terms for treatment and pooled country with ranked baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Testing for percent change from baseline was only carried out for given endpoint if corresponding numeric change result was statistically significant.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was based on a RANKED ANCOVA model with terms for treatment and pooled country with ranked baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Testing for percent change from baseline was only carried out for given endpoint if corresponding numeric change result was statistically significant.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of UUI Episodes Per 24 Hours at Week 4.</title>
        <description>UUI episodes were defined as those with the USS rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
        <time_frame>Week 4</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with BL UUI &gt;0 per 24 hours and non-missing change from BL to Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of UUI Episodes Per 24 Hours at Week 4.</title>
          <description>UUI episodes were defined as those with the USS rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with BL UUI &gt;0 per 24 hours and non-missing change from BL to Week 4.</population>
          <units>Episodes per 24 hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="715"/>
                <count group_id="O2" value="364"/>
                <count group_id="O3" value="704"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.55" spread="0.09"/>
                    <measurement group_id="O2" value="-1.99" spread="0.12"/>
                    <measurement group_id="O3" value="-2.75" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.02</ci_lower_limit>
            <ci_upper_limit>-0.50</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0662</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of UUI Episodes Per 24 Hours at Week 4.</title>
        <description>UUI episodes were defined as those with the USS rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
        <time_frame>Week 4</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with BL UUI &gt;0 per 24 hours and non-missing change from BL to Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of UUI Episodes Per 24 Hours at Week 4.</title>
          <description>UUI episodes were defined as those with the USS rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with BL UUI &gt;0 per 24 hours and non-missing change from BL to Week 4.</population>
          <units>Episodes per 24 hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="715"/>
                <count group_id="O2" value="364"/>
                <count group_id="O3" value="704"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-77.78" lower_limit="-100.00" upper_limit="244.44"/>
                    <measurement group_id="O2" value="-60.50" lower_limit="-100.00" upper_limit="283.33"/>
                    <measurement group_id="O3" value="-82.48" lower_limit="-100.00" upper_limit="500.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on a RANKED ANCOVA model with terms for treatment and pooled country with ranked baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Testing for percent change from baseline was only carried out for given endpoint if corresponding numeric change result was statistically significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was based on a RANKED ANCOVA model with terms for treatment and pooled country with ranked baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Testing for percent change from baseline was only carried out for given endpoint if corresponding numeric change result was statistically significant</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of UUI Episodes Per 24 Hours at Week 12.</title>
        <description>UUI episodes were defined as those with the USS rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
        <time_frame>Week 12</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. LOCF was used to impute missing data at Week 12. The analysis included participants with BL UUI &gt;0 per 24 hours and non-missing change from BL to Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of UUI Episodes Per 24 Hours at Week 12.</title>
          <description>UUI episodes were defined as those with the USS rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. LOCF was used to impute missing data at Week 12. The analysis included participants with BL UUI &gt;0 per 24 hours and non-missing change from BL to Week 12.</population>
          <units>Episodes per 24 hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="733"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="718"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-93.75" lower_limit="-100.00" upper_limit="437.50"/>
                    <measurement group_id="O2" value="-78.89" lower_limit="-100.00" upper_limit="350.00"/>
                    <measurement group_id="O3" value="-100.00" lower_limit="-100.00" upper_limit="325.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on a RANKED ANCOVA model with terms for treatment and pooled country with ranked baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Testing for percent change from baseline was only carried out for given endpoint if corresponding numeric change result was statistically significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on a RANKED ANCOVA model with terms for treatment and pooled country with ranked baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Testing for percent change from baseline was only carried out for given endpoint if corresponding numeric change result was statistically significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was based on a RANKED ANCOVA model with terms for treatment and pooled country with ranked baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Testing for percent change from baseline was only carried out for given endpoint if corresponding numeric change result was statistically significant</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Micturition-Related Urgency Episodes Per 24 Hours at Week 4.</title>
        <description>The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to (&gt;=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
        <time_frame>Week 4</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with BL Micturition-related urgency episodes &gt;0 per 24 hours and non-missing change from BL to Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Micturition-Related Urgency Episodes Per 24 Hours at Week 4.</title>
          <description>The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to (&gt;=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with BL Micturition-related urgency episodes &gt;0 per 24 hours and non-missing change from BL to Week 4.</population>
          <units>Episodes per 24 hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="715"/>
                <count group_id="O2" value="364"/>
                <count group_id="O3" value="705"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.89" spread="0.18"/>
                    <measurement group_id="O2" value="-1.85" spread="0.23"/>
                    <measurement group_id="O3" value="-3.40" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, and centered baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-1.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.04</ci_lower_limit>
            <ci_upper_limit>-1.06</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, and centered baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0121</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.92</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, and centered baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-1.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.52</ci_lower_limit>
            <ci_upper_limit>-0.55</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Micturition-Related Urgency Episodes Per 24 Hours at Week 12.</title>
        <description>The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to (&gt;=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
        <time_frame>Week 12</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. LOCF was used to impute missing data at Week 12. The analysis included participants with BL Micturition-Related Urgency Episodes &gt;0 per 24 hours and non-missing change from BL to Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Micturition-Related Urgency Episodes Per 24 Hours at Week 12.</title>
          <description>The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to (&gt;=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. LOCF was used to impute missing data at Week 12. The analysis included participants with BL Micturition-Related Urgency Episodes &gt;0 per 24 hours and non-missing change from BL to Week 12.</population>
          <units>Episodes per 24 hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="733"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="719"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.23" spread="0.19"/>
                    <measurement group_id="O2" value="-2.99" spread="0.25"/>
                    <measurement group_id="O3" value="-5.01" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, and centered baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-2.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.55</ci_lower_limit>
            <ci_upper_limit>-1.49</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, and centered baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.22</ci_lower_limit>
            <ci_upper_limit>-0.34</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, and centered baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-1.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.77</ci_lower_limit>
            <ci_upper_limit>-0.71</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Micturition-Related Urgency Episodes Per 24 Hours at Week 4.</title>
        <description>The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to (&gt;=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
        <time_frame>Week 4</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with BL Micturition-Related Urgency Episodes &gt;0 per 24 hours and non-missing change from BL to Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Micturition-Related Urgency Episodes Per 24 Hours at Week 4.</title>
          <description>The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to (&gt;=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with BL Micturition-Related Urgency Episodes &gt;0 per 24 hours and non-missing change from BL to Week 4.</population>
          <units>Participant</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="715"/>
                <count group_id="O2" value="364"/>
                <count group_id="O3" value="705"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.26" lower_limit="-100.00" upper_limit="280.00"/>
                    <measurement group_id="O2" value="-14.70" lower_limit="-100.00" upper_limit="716.67"/>
                    <measurement group_id="O3" value="-27.27" lower_limit="-100.00" upper_limit="150.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on a RANKED ANCOVA model with terms for treatment and pooled country with ranked baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Testing for percent change from baseline was only carried out for given endpoint if corresponding numeric change result was statistically significant.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on a RANKED ANCOVA model with terms for treatment and pooled country with ranked baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0348</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Testing for percent change from baseline was only carried out for given endpoint if corresponding numeric change result was statistically significant.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was based on a RANKED ANCOVA model with terms for treatment and pooled country with ranked baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Testing for percent change from baseline was only carried out for given endpoint if corresponding numeric change result was statistically significant.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Micturition-Related Urgency Episodes Per 24 Hours at Week 12.</title>
        <description>The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to (&gt;=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
        <time_frame>Week 12</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. LOCF was used to impute missing data at Week 12. The analysis included participants with BL Micturition-Related Urgency Episodes &gt;0 per 24 hours and non-missing change from BL to Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Micturition-Related Urgency Episodes Per 24 Hours at Week 12.</title>
          <description>The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to (&gt;=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. LOCF was used to impute missing data at Week 12. The analysis included participants with BL Micturition-Related Urgency Episodes &gt;0 per 24 hours and non-missing change from BL to Week 12.</population>
          <units>Participant</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="733"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="719"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.88" lower_limit="-100.00" upper_limit="310.00"/>
                    <measurement group_id="O2" value="-22.73" lower_limit="-100.00" upper_limit="716.67"/>
                    <measurement group_id="O3" value="-44.29" lower_limit="-100.00" upper_limit="233.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on a RANKED ANCOVA model with terms for treatment and pooled country with ranked baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Testing for percent change from baseline was only carried out for given endpoint if corresponding numeric change result was statistically significant.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on a RANKED ANCOVA model with terms for treatment and pooled country with ranked baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Testing for percent change from baseline was only carried out for given endpoint if corresponding numeric change result was statistically significant.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was based on a RANKED ANCOVA model with terms for treatment and pooled country with ranked baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Testing for percent change from baseline was only carried out for given endpoint if corresponding numeric change result was statistically significant.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change From Baseline in Patient Perception of Bladder Condition (PPBC) at Week 12.</title>
        <description>PPBC: a self-administered, single-item, questionnaire that asks participants to describe their perception of their bladder-related problems. The PPBC assessment is rated on a 6-point scale: 1=no problems at all, 2=some very minor problems, 3=some minor problems, 4=moderate problems, 5=severe problems, 6=many severe problems. Improvement is defined as negative change from baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with non-missing change from baseline value at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change From Baseline in Patient Perception of Bladder Condition (PPBC) at Week 12.</title>
          <description>PPBC: a self-administered, single-item, questionnaire that asks participants to describe their perception of their bladder-related problems. The PPBC assessment is rated on a 6-point scale: 1=no problems at all, 2=some very minor problems, 3=some minor problems, 4=moderate problems, 5=severe problems, 6=many severe problems. Improvement is defined as negative change from baseline.</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with non-missing change from baseline value at Week 12.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="700"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deterioration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172"/>
                    <measurement group_id="O2" value="122"/>
                    <measurement group_id="O3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210"/>
                    <measurement group_id="O2" value="105"/>
                    <measurement group_id="O3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change at Week 12- deterioration, no change, minor improvement and major improvement: Cochran-Mantel-Haenszel (CMH) test with modified ridit scoring controlling for country was used to calculate p-value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change at Week 12- deterioration, no change, minor improvement and major improvement: Cochran-Mantel-Haenszel (CMH) test with modified ridit scoring controlling for country was used to calculate p-value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0057</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Week 12- deterioration, no change, minor improvement and major improvement: Cochran-Mantel-Haenszel (CMH) test with modified ridit scoring controlling for country was used to calculate p-value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change From Baseline in Urgency Perception Scale (UPS) at Week 12.</title>
        <description>UPS: single-item, self-administered validated questionnaire. Participant answered: Which of the following would typically describe your experience when you have a desire to urinate? on a 3-point scale, 1=usually not able to hold urine; 2=usually able to hold urine (without leaking) until I reach a toilet if I go to the toilet immediately; 3= usually able to finish what I am doing before going to the toilet (without leaking). Change = observation minus baseline. Results categorized as Deterioration (Negative change); no change (Score change=0); improvement (Positive change).</description>
        <time_frame>Week 12</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with non-missing change from baseline value at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change From Baseline in Urgency Perception Scale (UPS) at Week 12.</title>
          <description>UPS: single-item, self-administered validated questionnaire. Participant answered: Which of the following would typically describe your experience when you have a desire to urinate? on a 3-point scale, 1=usually not able to hold urine; 2=usually able to hold urine (without leaking) until I reach a toilet if I go to the toilet immediately; 3= usually able to finish what I am doing before going to the toilet (without leaking). Change = observation minus baseline. Results categorized as Deterioration (Negative change); no change (Score change=0); improvement (Positive change).</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with non-missing change from baseline value at Week 12.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="700"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deterioration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361"/>
                    <measurement group_id="O2" value="193"/>
                    <measurement group_id="O3" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302"/>
                    <measurement group_id="O2" value="132"/>
                    <measurement group_id="O3" value="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change at Week 12- deterioration, no change, minor improvement and major improvement: Cochran-Mantel-Haenszel (CMH) test with modified ridit scoring controlling for country was used to calculate p-value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change at Week 12- deterioration, no change, minor improvement and major improvement: Cochran-Mantel-Haenszel (CMH) test with modified ridit scoring controlling for country was used to calculate p-value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0091</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Week 12- deterioration, no change, minor improvement and major improvement: Cochran-Mantel-Haenszel (CMH) test with modified ridit scoring controlling for country was used to calculate p-value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3901</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at Week 12.</title>
        <description>OAB-q: a self-administered, 33-item, questionnaire that assesses how much the participant has been bothered by selected bladder symptoms. Each item rated by participant on Likert scale 1 (not at all) to 6 (a very great deal). Symptom bother score derived as sum of scores for questions 1-8; lowest possible raw score: 8; highest possible score: 48. Data analyzed based on transformation of the score to a 0 to 100 scale [(Actual total raw score  lowest possible value of raw score)/range]*100. Higher scores values indicative of greater symptom bother.</description>
        <time_frame>Week 12</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with non-missing change from baseline value at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at Week 12.</title>
          <description>OAB-q: a self-administered, 33-item, questionnaire that assesses how much the participant has been bothered by selected bladder symptoms. Each item rated by participant on Likert scale 1 (not at all) to 6 (a very great deal). Symptom bother score derived as sum of scores for questions 1-8; lowest possible raw score: 8; highest possible score: 48. Data analyzed based on transformation of the score to a 0 to 100 scale [(Actual total raw score  lowest possible value of raw score)/range]*100. Higher scores values indicative of greater symptom bother.</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with non-missing change from baseline value at Week 12.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="347"/>
                <count group_id="O3" value="678"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.19" spread="1.09"/>
                    <measurement group_id="O2" value="-22.41" spread="1.43"/>
                    <measurement group_id="O3" value="-34.88" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change at Week 12- ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction was used to calculate p-value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-12.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.49</ci_lower_limit>
            <ci_upper_limit>-9.45</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change at Week 12- ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction was used to calculate p-value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-4.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.15</ci_lower_limit>
            <ci_upper_limit>-2.22</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Week 12- ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction was used to calculate p-value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-7.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.78</ci_lower_limit>
            <ci_upper_limit>-4.78</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Related Quality of Life (HRQL)-Coping Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.</title>
        <description>OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (not at all) to 6 (a very great deal). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.</description>
        <time_frame>Week 12</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with non-missing change from BL value at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Related Quality of Life (HRQL)-Coping Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.</title>
          <description>OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (not at all) to 6 (a very great deal). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with non-missing change from BL value at Week 12.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="347"/>
                <count group_id="O3" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.69" spread="1.18"/>
                    <measurement group_id="O2" value="20.91" spread="1.55"/>
                    <measurement group_id="O3" value="31.38" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>10.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.67</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.20</ci_lower_limit>
            <ci_upper_limit>13.73</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>4.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.01</ci_lower_limit>
            <ci_upper_limit>7.36</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>5.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.53</ci_lower_limit>
            <ci_upper_limit>9.03</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Related Quality of Life (HRQL)-Concern Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.</title>
        <description>OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (not at all) to 6 (a very great deal). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.</description>
        <time_frame>Week 12</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with non-missing change from BL value at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Related Quality of Life (HRQL)-Concern Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.</title>
          <description>OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (not at all) to 6 (a very great deal). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with non-missing change from BL value at Week 12.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="347"/>
                <count group_id="O3" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.82" spread="1.15"/>
                    <measurement group_id="O2" value="20.27" spread="1.51"/>
                    <measurement group_id="O3" value="31.18" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>10.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.73</ci_lower_limit>
            <ci_upper_limit>14.09</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>4.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.76</ci_lower_limit>
            <ci_upper_limit>6.96</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>6.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.39</ci_lower_limit>
            <ci_upper_limit>9.72</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Related Quality of Life (HRQL)-Sleep Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.</title>
        <description>OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (not at all) to 6 (a very great deal). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.</description>
        <time_frame>Week 12</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with non-missing change from BL value at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Related Quality of Life (HRQL)-Sleep Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.</title>
          <description>OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (not at all) to 6 (a very great deal). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with non-missing change from BL value at Week 12.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="347"/>
                <count group_id="O3" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.97" spread="1.10"/>
                    <measurement group_id="O2" value="18.25" spread="1.45"/>
                    <measurement group_id="O3" value="25.71" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>7.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.40</ci_lower_limit>
            <ci_upper_limit>10.51</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0034</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>3.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.24</ci_lower_limit>
            <ci_upper_limit>6.23</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0164</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>3.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>6.76</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Related Quality of Life (HRQL)-Social Interaction Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.</title>
        <description>OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (not at all) to 6 (a very great deal). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.</description>
        <time_frame>Week 12</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with non-missing change from BL value at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Related Quality of Life (HRQL)-Social Interaction Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.</title>
          <description>OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (not at all) to 6 (a very great deal). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with non-missing change from BL value at Week 12.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="347"/>
                <count group_id="O3" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.43" spread="0.89"/>
                    <measurement group_id="O2" value="12.61" spread="1.17"/>
                    <measurement group_id="O3" value="20.11" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>7.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.03</ci_lower_limit>
            <ci_upper_limit>9.97</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>3.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.65</ci_lower_limit>
            <ci_upper_limit>5.70</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0023</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>3.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.36</ci_lower_limit>
            <ci_upper_limit>6.28</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Related Quality of Life (HRQL)-Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.</title>
        <description>OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (not at all) to 6 (a very great deal). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.</description>
        <time_frame>Week 12</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with non-missing change from BL value at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Related Quality of Life (HRQL)-Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.</title>
          <description>OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (not at all) to 6 (a very great deal). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with non-missing change from BL value at Week 12.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="347"/>
                <count group_id="O3" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.70" spread="1.02"/>
                    <measurement group_id="O2" value="18.57" spread="1.33"/>
                    <measurement group_id="O3" value="27.94" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>9.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.56</ci_lower_limit>
            <ci_upper_limit>12.18</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>4.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.93</ci_lower_limit>
            <ci_upper_limit>6.53</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was based on an ANCOVA model with terms for treatment, pooled country, centered baseline value and centered baseline by treatment interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>5.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.34</ci_lower_limit>
            <ci_upper_limit>7.94</ci_upper_limit>
            <estimate_desc>Note- Standard Error of the Mean in the table refers to Standard Error of the Least Squares Mean.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Became Dry at Week 4.</title>
        <description>Percentage of participants with no UUI episode for the three day diary, the numerator being the number of participants with no UUI at a visit and the denominator the total number of participants with UUI&gt;0 at baseline. UUI episodes defined as those with USS rating of 5 (unable to hold; leak urine) in the diary</description>
        <time_frame>Week 4</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with baseline UUI &gt;0 per 24 hours and non-missing change from baseline to Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Became Dry at Week 4.</title>
          <description>Percentage of participants with no UUI episode for the three day diary, the numerator being the number of participants with no UUI at a visit and the denominator the total number of participants with UUI&gt;0 at baseline. UUI episodes defined as those with USS rating of 5 (unable to hold; leak urine) in the diary</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. The analysis included participants with baseline UUI &gt;0 per 24 hours and non-missing change from baseline to Week 4.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="715"/>
                <count group_id="O2" value="364"/>
                <count group_id="O3" value="704"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5"/>
                    <measurement group_id="O2" value="26.4"/>
                    <measurement group_id="O3" value="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was obtained from a Cochran-Mantel-Haenszel (CMH) general association test stratified by country.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0016</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was obtained from a Cochran-Mantel-Haenszel (CMH) general association test stratified by country.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8121</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was obtained from a Cochran-Mantel-Haenszel (CMH) general association test stratified by country.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Became Dry at Week 12.</title>
        <description>Percentage of participants with no UUI episode for the three day diary, the numerator being the number of participants with no UUI at a visit and the denominator the total number of participants with UUI &gt;0 at baseline. UUI episodes defined as those with USS rating of 5 (unable to hold; leak urine) in the diary.</description>
        <time_frame>Week 12</time_frame>
        <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. Number of participants with Baseline UUI &gt;0 per 24 hours and non-missing change from baseline to Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 Milligram (mg)</title>
            <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received one tablet of placebo per day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Became Dry at Week 12.</title>
          <description>Percentage of participants with no UUI episode for the three day diary, the numerator being the number of participants with no UUI at a visit and the denominator the total number of participants with UUI &gt;0 at baseline. UUI episodes defined as those with USS rating of 5 (unable to hold; leak urine) in the diary.</description>
          <population>The FAS included all participants who took at least 1 dose of assigned study drug and had at least 1 BL or post-BL efficacy assessment. Number of participants with Baseline UUI &gt;0 per 24 hours and non-missing change from baseline to Week 12.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="733"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="718"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2"/>
                    <measurement group_id="O2" value="39.5"/>
                    <measurement group_id="O3" value="57.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was obtained from a Cochran-Mantel-Haenszel (CMH) general association test stratified by country.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-value was obtained from a Cochran-Mantel-Haenszel (CMH) general association test stratified by country.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was obtained from a Cochran-Mantel-Haenszel (CMH) general association test stratified by country.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0027</p_value>
            <p_value_desc>A closed-testing procedure was used for the treatment comparison.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 28 days after the last dose of the study drug</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fesoterodine 4 Milligram (mg)</title>
          <description>Participants received one sustained-release (SR) tablet with 4 mg fesoterodine once daily for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received one tablet of placebo per day for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Fesoterodine 8 mg</title>
          <description>Participants received one SR tablet with 4 mg fesoterodine for 1 week, followed by dose escalation to 8 mg once daily for 11 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRAv15.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Herpes simplex ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Post procedural hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign ovarian tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Uterine hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Peripheral ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRAv15.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="297" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="349" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Eustachian tube obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Conjunctival irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Eye allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Scintillating scotoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="203" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Palatal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Peptic ulcer hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Tongue disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Tongue dry</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Sluggishness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Suprapubic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Asymptomatic bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>External ear cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Gingival infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Limb crushing injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bacterial test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Biopsy breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Red blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Smear buccal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Smear cervix abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Vitamin B complex deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Vitamin B12 deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Muscle disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Anosmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Parosmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Radiculitis lumbosacral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Depressive symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Loss of libido</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Performance fear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Premature ejaculation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Tic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Enuresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Glycosuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Haematinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Terminal dribbling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Urge incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Urinary hesitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Urine flow decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Premenstrual syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Uterine spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Generalised erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Granuloma annulare</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Telangiectasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Aneurysm repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Haemorrhoid operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Mass excision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Mole excision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Skin lesion excision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Tendon operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="779"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="790"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="779"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

